In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi

被引：41

作者：

Cuenca-Estrella, M ^{[1
]}

Gomez-Lopez, A ^{[1
]}

Mellado, E ^{[1
]}

Garcia-Effron, G ^{[1
]}

Monzon, A ^{[1
]}

Rodriguez-Tudela, JL ^{[1
]}

机构：

[1] Inst Salud Carlos III, Serv Micol, Ctr Nacl Microbiol, Majadahonda 28220, Madrid, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 12期

关键词：

D O I：

10.1128/AAC.49.12.5136-5138.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activities of ravuconazole against 575 clinical strains of Aspergillus spp. and 348 nondermatophyte non-Aspergillus spp. were analyzed. Ravuconazole was active against Aspergillus spp., other hyaline filamentous fungi, black molds, and some Mucorales. Species such as Scedosporium prolificans, Fusarium spp., and Scopulariopsis spp. were resistant to the triazole.

引用

页码：5136 / 5138

页数：3

共 28 条

[1] In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1193-1199

[2] In vitro activities of four novel triazoles against Scedosporium spp. [J].

Carrillo, AJ ;

Guarro, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2151-2153

[3] In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates [J].

Cuenca-Estrella, M ;

Gomez-Lopez, A ;

Mellado, E ;

Garcia-Effron, G ;

Rodriguez-Tudela, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3107-3111

[4] Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents [J].

Cuenca-Estrella, M ;

Gomez-Lopez, A ;

Mellado, E ;

Buitrago, MJ ;

Monzón, A ;

Rodriguez-Tudela, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2339-2341

[5] Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum [J].

Cuenca-Estrella, M ;

Ruiz-Díez, B ;

Martínez-Suárez, JV ;

Monzón, A ;

Rodríguez-Tudela, JL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :149-151

[6] Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].

Denning, DW ;

Radford, SA ;

Oakley, KL ;

Hall, L ;

Johnson, EM ;

Warnock, DW .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414

[7] Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi [J].

Diekema, DJ ;

Messer, SA ;

Hollis, RJ ;

Jones, RN ;

Pfaller, MA .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3623-3626

[8] Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.:: NCCLS Collaborative Study [J].

Espinel-Ingroff, A ;

Fothergill, A ;

Peter, J ;

Rinaldi, MG ;

Walsh, TJ .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (09) :3204-3208

[9] In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole [J].

Fung-Tomc, JC ;

White, TC ;

Minassian, B ;

Huczko, E ;

Bonner, DP .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (02) :163-167

[10]

Fung-Tomc JC, 1998, ANTIMICROB AGENTS CH, V42, P313

← 1 2 3 →